A BILL 
To amend the Biologics Price Competition and Innovation 
Act of 2009 to streamline the transition of certain prod-
ucts from approval as a drug to licensure as a biological 
product, and for other purposes. 
Be it enacted by the Senate and House of Representa-
1
tives of the United States of America in Congress assembled, 
2
SECTION 1. SHORT TITLE. 
3
This Act may be cited as the ‘‘Lower Insulin Costs 
4
Now Act’’. 
5
01:45 Dec 27, 2019
H5444
2 
•HR 5444 IH
SEC. 2. STREAMLINING THE TRANSITION OF BIOLOGICAL 
1
PRODUCTS. 
2
Section 7002(e)(4) of the Biologics Price Competition 
3
and Innovation Act of 2009 (Public Law 111–148) is 
4
amended— 
5
(1) by striking ‘‘An approved application’’ and 
6
inserting the following: 
7
‘‘(A) IN GENERAL.—An approved applica-
8
tion’’; and 
9
(2) by adding at the end the following: 
10
‘‘(B) TREATMENT OF CERTAIN APPLICA-
11
TIONS.— 
12
‘‘(i) IN GENERAL.—With respect to an 
13
application for a biological product sub-
14
mitted under subsection (b) or (j) of sec-
15
tion 505 of the Federal Food, Drug, and 
16
Cosmetic Act (21 U.S.C. 355) that is filed 
17
not later than March 23, 2019, and is not 
18
approved as of March 23, 2020, the Sec-
19
retary shall continue to review such appli-
20
cation under such section 505, after March 
21
23, 2020. 
22
‘‘(ii) EFFECT
ON
LISTED
DRUGS.— 
23
Only for purposes of carrying out clause 
24
(i), with respect to any applicable listed 
25
01:45 Dec 27, 2019
H5444
3 
•HR 5444 IH
drug with respect to such application, the 
1
following shall apply: 
2
‘‘(I) Any drug that is a biological 
3
product that has been deemed licensed 
4
under section 351 of the Public 
5
Health Service Act (42 U.S.C. 262) 
6
pursuant to subparagraph (A) and 
7
that is referenced in an application 
8
described in clause (i), shall continue 
9
to be identified as a listed drug on the 
10
list published pursuant to section 
11
505(j)(7) of the Federal Food, Drug, 
12
and Cosmetic Act, and the informa-
13
tion for such drug on such list shall 
14
not be revised after March 20, 2020, 
15
until— 
16
‘‘(aa) such drug is removed 
17
from such list in accordance with 
18
subclause (III) or subparagraph 
19
(C) of such section 505(j)(7); or 
20
‘‘(bb) this subparagraph no 
21
longer has force or effect. 
22
‘‘(II) Any drug that is a biologi-
23
cal product that has been deemed li-
24
censed under section 351 of the Pub-
25
01:45 Dec 27, 2019
H5444
4 
•HR 5444 IH
lic Health Service Act (42 U.S.C. 
1
262) pursuant to subparagraph (A) 
2
and that is referenced in an applica-
3
tion described in clause (i) shall be 
4
subject only to requirements applica-
5
ble to biological products licensed 
6
under such section. 
7
‘‘(III) Upon approval under sub-
8
section (c) or (j) of section 505 of the 
9
Federal Food, Drug, and Cosmetic 
10
Act of an application described in 
11
clause (i), the Secretary shall remove 
12
from the list published pursuant to 
13
section 505(j)(7) of the Federal Food, 
14
Drug, and Cosmetic Act any listed 
15
drug that is a biological product that 
16
has been deemed licensed under sec-
17
tion 351 of the Public Health Service 
18
Act pursuant to subparagraph (A) 
19
and that is referenced in such ap-
20
proved application, unless such listed 
21
drug is referenced in one or more ad-
22
ditional 
applications 
described 
in 
23
clause (i). 
24
01:45 Dec 27, 2019
H5444
5 
•HR 5444 IH
‘‘(iii) 
DEEMED
LICENSURE.—Upon 
1
approval of an application described in 
2
clause (i), such approved application shall 
3
be deemed to be a license for the biological 
4
product under section 351 of the Public 
5
Health Service Act. 
6
‘‘(iv) RULE OF CONSTRUCTION.— 
7
‘‘(I) APPLICATION
OF
CERTAIN 
8
PROVISIONS.— 
9
‘‘(aa) 
PATENT
CERTIFI-
10
CATION OR STATEMENT.—An ap-
11
plication described in clause (i) 
12
shall contain a patent certifi-
13
cation or statement described in, 
14
as applicable, section 505(b)(2) 
15
of the Federal Food, Drug, and 
16
Cosmetic Act or clauses (vii) and 
17
(viii) of section 505(j)(2)(A) of 
18
such Act and, with respect to any 
19
listed drug referenced in such ap-
20
plication, comply with related re-
21
quirements concerning any timely 
22
filed patent information listed 
23
pursuant to section 505(j)(7). 
24
01:45 Dec 27, 2019
H5444
6 
•HR 5444 IH
‘‘(bb) 
DATE
OF
AP-
1
PROVAL.—The earliest possible 
2
date on which any pending appli-
3
cation described in clause (i) may 
4
be approved shall be determined 
5
based on— 
6
‘‘(AA) the last expira-
7
tion date of any applicable 
8
period of exclusivity that 
9
would prevent such approval 
10
and that is described in sec-
11
tion 
505(c)(3)(E), 
12
505(j)(5)(B)(iv), 
13
505(j)(5)(F), 505A, 505E, 
14
or 527 of the Federal Food, 
15
Drug, and Cosmetic Act; 
16
and 
17
‘‘(BB) if the application 
18
was submitted pursuant to 
19
section 505(b)(2) of the 
20
Federal Food, Drug, and 
21
Cosmetic Act and references 
22
any listed drug, the last ap-
23
plicable 
date 
determined 
24
under 
subparagraph 
(A), 
25
01:45 Dec 27, 2019
H5444
7 
•HR 5444 IH
(B), 
or 
(C) 
of 
section 
1
505(c)(3) of such Act, or, if 
2
the application was sub-
3
mitted under section 505(j) 
4
of such Act, the last applica-
5
ble date determined under 
6
clause (i), (ii), or (iii) of sec-
7
tion 505(j)(5)(B). 
8
‘‘(II) EXCLUSIVITY.—Nothing in 
9
this subparagraph shall be construed 
10
to affect section 351(k)(7)(D) of the 
11
Public Health Service Act. 
12
‘‘(v) LISTING.—The Secretary may 
13
continue to review an application after 
14
March 23, 2020, pursuant to clause (i), 
15
and continue to identify any applicable list-
16
ed drug pursuant to clause (ii) on the list 
17
published pursuant to section 505(j)(7) of 
18
the Federal Food, Drug, and Cosmetic 
19
Act, even if such review or listing may re-
20
veal the existence of such application and 
21
the identity of any listed drug for which 
22
the investigations described in section 
23
505(b)(1)(A) of the Federal Food, Drug, 
24
and Cosmetic Act are relied upon by the 
25
01:45 Dec 27, 2019
H5444
8 
•HR 5444 IH
applicant for approval of the pending ap-
1
plication. Nothing in this subparagraph 
2
shall be construed as authorizing the Sec-
3
retary to disclose any other information 
4
that is a trade secret or confidential infor-
5
mation described in section 552(b)(4) of 
6
title 5, United States Code. 
7
‘‘(vi) SUNSET.—Beginning on October 
8
1, 2022, this subparagraph shall have no 
9
force or effect and any applications de-
10
scribed in clause (i) that have not been ap-
11
proved shall be deemed withdrawn.’’. 
12
Æ 
01:45 Dec 27, 2019
H5444
